Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) ...Middle East

- Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity - - Positive safety...

Hence then, the article about tyra biosciences reports interim clinical proof of concept data for tyra 300 an investigational oral fgfr3 selective inhibitor in phase 1 2 surf301 study in patients with metastatic urothelial cancer muc was published today ( Friday 25/10/2024 - 01:28 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) )

Also on site :

• AI startup Rocket offers vibe McKinsey-style reports at a fraction of the cost
• JP Morgan Chase head warns of unexpected interest rate shocks as a result of Iran war
• This 1954 Film Ranked as Alfred Hitchcock's No. 1 'Masterpiece'